Simple Summary Lung cancer is one of the most common human cancers and the leading
cause of cancer-related mortality worldwide. The advent of immunotherapy for the treatment …

Background Immune checkpoint inhibitors (ICIs) have shown significant improvements in
patients with advanced non–small cell lung cancer (NSCLC). One of the major issues with …

Background The optimal treatment duration of ICIs for patients with advanced NSCLC
remains uncertain. In phase 3 clinical trials, treatment continued for 2 years or until disease …

Background/Aim: Immune checkpoint inhibitors (ICIs) have revolutionized advanced non-
small cell lung cancer (NSCLC) treatment. Even patients with epidermal growth factor …

Methods We conducted a retrospective observational study of all patients with mNSCLC
treated with ICIs, with or without combination chemotherapy, at 3 Mayo Clinic sites between …

Introduction Immune checkpoint inhibitor (ICI) therapy is an established treatment for
advanced non‐small‐cell lung cancer (NSCLC) and programmed death ligand‐1 (PD‐L1) …

To realize the full potential of promising new anticancer drugs, it is of paramount importance
to administer them at the right dose. The aim of this educational article is to provide several …

Complete response of non–small cell lung cancer (NSCLC) with immune checkpoint
inhibitor (ICI) monotherapy is rare. Here, we encountered an elderly patient who showed …

An 80-year-old male patient was diagnosed to have squamous cell carcinoma of the lung
which had a high level of programmed death-ligand 1 (PD-L1) expression. He was …

Background/Aim: Patients with non-small-cell lung cancer treated with immune checkpoint
inhibitors (ICI) might be forced to discontinue treatment for various reasons. We conducted a …